Laboratory Considerations for Clinical Trials
Science:Life Sciences
A liquid biopsy is a minimally invasive alternative to a more traditional surgical solid tumor biopsy.
In this episode, Dr. Stephanie Hastings, genomics product lead at Q Squared Solutions, lays out the considerations for liquid biopsy collection and the type of information that can be gathered from circulating free DNA (cfDNA).
The main approaches comprise for evaluating cfDNA are:
- specific mutation detection to help support targeted therapies
- broader sequencing technologies to enable biomarker evaluations
- custom sequencing panels to support clinical trial assay development
She describes the typical panels for each of the approaches, the sample collection requirements and how these analyses are implemented on a global scale.
More Episodes
What is the Role of Digital Pathology in Clinical Trials
2023-11-17
200
2023-11-17
200
Flexible Approaches for Biotech Companies in Clinical Trials
2022-06-22
284
2022-06-22
284
Risk Management for Biotech Companies in Clinical Trials
2022-05-16
216
2022-05-16
216
Managing Sample Data from Vendors
2021-09-14
248
2021-09-14
248
Automation within an ADME Laboratory
2021-08-26
209
2021-08-26
209
Bioanalytical Automation of Samples
2021-07-30
183
2021-07-30
183
Consent Tracking for Clinical Samples
2021-07-28
185
2021-07-28
185
Tracking Clinical Trial Samples
2021-07-28
178
2021-07-28
178
Avoiding Canceled Tests in Pediatric Samples
2021-02-02
145
2021-02-02
145
Covid Vaccine Testing
2020-09-15
195
2020-09-15
195
Hybrid Assays for Protein Bioanalysis
2020-07-29
157
2020-07-29
157
High Throughput ADME Testing
2020-07-29
99
2020-07-29
99
Get this podcast on your
phone, FREE
